TOPICAL GLUCOCORTICOID THERAPY OF PSORIASIS AND ATOPIC DERMATITIS


DOI: https://dx.doi.org/10.18565/pharmateca.2018.s5.58-63

V.A. Molochkov (1), O.V. Matveeva (2)

1 Department of Dermatovenereology and Dermatooncology, Moscow Regional Scientific Research Clinical Institute n.a. M.F. Vladimirsky, Moscow, Russia; 2 GSK, Moscow, Russia
Topical therapy with glucocorticosteroids (GCSs) plays an important role in the treatment of steroid-sensitive dermatoses, including psoriasis and atopic dermatitis, due to the anti-inflammatory, antiproliferative, vasoconstrictive and hyposensitizing effects of these drugs. Dermovate – 0.05% clobetasol propionate is a very strong corticosteroid, allowing to quickly achieve full clinical effect against the background of a low concentration of the active substance, which reduces the risk of systemic side effects and has a favorable safety profile when used correctly. The rational use of topical GCSs in psoriasis and atopic dermatitis is discussed in detail.
Keywords: topical glucocorticosteroids, dermovate, psoriasis, atopic dermatitis

About the Autors


Corresponding author: V.А. Molochkov – MD, Prof., Head of the Department of Dermatovenereology and Dermatooncology, Moscow Regional Scientific Research Clinical Institute n.a. M.F. Vladimirsky, Moscow, Russia; e-mail: vlmolochkov@yandex.ru


Бионика Медиа